Clinical Trial Update: A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study of LY2875358 in participants with non-small cell lung cancer harboring activating EGFR mutations; the trial h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LY2875358

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED